A newly published systematic review titled on psilocybin’s effects on obsessive‑compulsive behaviours provides an up-to-date synthesis of research into the compound’s potential for treating OCD and...
Last week, the U.S.
Arcadia Medicine, a San Francisco-based biotech startup developing MDMA-like empathogens, this month closed roughly $9.25 million in seed financing and won FDA clearance to begin human...
Dr. Celia Morgan is one of the UK’s leading figures in ketamine and psychedelic research, especially in the domain of addiction and mental health.
For the first time, data from real-world application of psilocybin treatment under a regulated program was published by one of the Oregon clinics providing treatment.
Professor David Nutt stands out as a leading figure in modern psychedelic science, tirelessly pushing the boundaries of how drugs such as psilocybin, MDMA, LSD, DMT,...
On Friday, the Royal College of Psychiatrists has published a new report assessing the safety and efficacy of psychedelics and related substances as treatments for mental...
Psychedelic medicine took a major step forward this month as JAMA published results from the first randomized, placebo-controlled trial of LSD for anxiety.
A new article published in Nature by Dr.
AbbVie Inc.
By Jody Chu and James Bunn.
After a ten-month pause, Psychedelic Health returns — renewed in purpose and ready to stand with an industry that has faced some of its most challenging...
